Archive for the ‘Halozyme Therapeutics Inc’ Category

Halozyme Therapeutics Inc

January 25th, 2016 | Posted in 2016, Halozyme Therapeutics Inc

Halozyme Therapeutics Inc., San Diego, entered into a $150 million credit agreement to fund the start of its Phase 3 study in pancreatic cancer. The credit agreement was secured by future royalties of Halozyme’s ENHANZE products, received only from the company’s collaborations with Roche and Baxalta. The financing comes shortly after Halozyme received an upfront payment of […]

Halozyme

January 9th, 2015 | Posted in 2014, Halozyme Therapeutics Inc

Halozyme Therapeutics, San Diego, has entered a collaboration and licencing agreement, worth potentially $580 million, with Janssen Biotech to development and commercialize products using its Enhancze technology. Janssen (a division of Johnson & Johnson) will initially pay $15 million it can use Halozyme’s products in its drug treatments. Then Halozyme will be eligible to received […]

Halozyme Therapeutics Inc

February 5th, 2014 | Posted in 2014, Halozyme Therapeutics Inc

Halozyme Therapeutics Inc. – San Diego:   Recently announced that the European Union “EU” Committee for Medicinal Products for Human Use has recommended that the European Commission approve its treatment of common forms of non-Hodgkin lymphoma.  Approval may take months.

Halozyme Therapeutics

December 4th, 2013 | Posted in 2013, Halozyme Therapeutics Inc

Halozyme Therapeutics – Revenues were tripled !!!!! in the 3rd quarter.  The San Diego company got most of its revenues from making the primary ingredient used in Herceptin SC, an injectable form of Roche’s cancer drug Herceptin, which was launched in Europe in the 3rd quarter.

Halozyme Therapeutics Inc

October 1st, 2013 | Posted in 2013, Halozyme Therapeutics Inc

Halozyme Therapeutics Inc. – San Diego:  The commercial launch of Herceptin SC in Europe has triggered a $10-million milestone under the License & Collaboration Agreement between Halozyme and Roche.

Halozyme Therapeutics Inc

September 4th, 2013 | Posted in 2013, Halozyme Therapeutics Inc

Halozyme Therapeutics Inc. – San Diego:  Recently announced that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a subcutaneous formulation of Herceptin for the treatment of HER2-positive breast cancer.  This formulation uses Halozyme’s recombinant human hyaluronidase and is administered in two to five minutes, rather than 30 to […]